Xenon Pharmaceuticals (NASDAQ:XENE) Sees Large Volume Increase on Analyst Upgrade

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) shares saw unusually-high trading volume on Wednesday after Wells Fargo & Company raised their price target on the stock from $49.00 to $68.00. Wells Fargo & Company currently has an overweight rating on the stock. Approximately 1,535,168 shares changed hands during trading, an increase of 22% from the previous session’s volume of 1,255,933 shares.The stock last traded at $60.2830 and had previously closed at $60.61.

XENE has been the topic of a number of other research reports. Guggenheim reiterated a “buy” rating and set a $90.00 target price on shares of Xenon Pharmaceuticals in a research note on Monday. JPMorgan Chase & Co. upped their price objective on Xenon Pharmaceuticals from $60.00 to $62.00 and gave the company an “overweight” rating in a report on Friday, January 9th. Jefferies Financial Group set a $100.00 price objective on Xenon Pharmaceuticals in a research report on Monday. HC Wainwright boosted their target price on shares of Xenon Pharmaceuticals from $53.00 to $74.00 and gave the company a “buy” rating in a research report on Tuesday. Finally, Stifel Nicolaus set a $66.00 price target on shares of Xenon Pharmaceuticals in a research note on Tuesday, February 10th. Two research analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Xenon Pharmaceuticals has an average rating of “Buy” and a consensus price target of $71.94.

Insider Activity

In other news, CEO Ian Mortimer sold 40,000 shares of the stock in a transaction on Friday, January 2nd. The stock was sold at an average price of $44.43, for a total transaction of $1,777,200.00. Following the sale, the chief executive officer directly owned 6,000 shares of the company’s stock, valued at approximately $266,580. This represents a 86.96% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Company insiders own 4.07% of the company’s stock.

Key Stories Impacting Xenon Pharmaceuticals

Here are the key news stories impacting Xenon Pharmaceuticals this week:

• Positive Sentiment: Positive Phase‑3 results for azetukalner in focal‑onset seizures — Xenon says the study met its goal and plans an NDA filing in Q3 2026, a major commercial catalyst that drove the recent sharp rally. XENE Stock Up as Azetukalner Meets Goal in Focal Onset Seizures Study
• Positive Sentiment: Multiple analyst upgrades and higher price targets followed the data (Needham, Deutsche Bank, HC Wainwright, Wells Fargo, Wedbush), increasing buy interest and supporting the stock’s re‑rating. Xenon Pharmaceuticals (NASDAQ:XENE) Stock Price Expected to Rise, Needham & Company LLC Analyst Says
• Neutral Sentiment: Upsized public offering priced at $57 to raise ~ $650M (with a 30‑day overallotment option) — materially strengthens the balance sheet and funds development, but its net impact depends on execution and how proceeds are deployed. Xenon Pharmaceuticals Announces Pricing of Upsized $650.0 Million Public Offering
• Negative Sentiment: Large offering and extra share count create dilution risk for existing holders; timing after a big run raises the chance of near‑term supply pressure. Xenon Pharmaceuticals Inc. Prices Upsized Public Offering, Anticipated Gross Proceeds of Approximately $650 Million
• Negative Sentiment: Some commentators flag valuation and execution risks despite strong efficacy (crowded ASO market, side‑effect profile, commercial execution), which could temper upside after the initial surge. Xenon: Shares Soar On Seizure Data, But Valuation May Be Overcooked
• Negative Sentiment: Following the trial announcement the stock experienced heavy one‑day gains (near 50%), which often leads to profit‑taking and higher intraday volatility. 50% and 61% Gains in a Single Day: Why XENE and RLMD Soared Today

Hedge Funds Weigh In On Xenon Pharmaceuticals

Several hedge funds and other institutional investors have recently made changes to their positions in XENE. Kestra Advisory Services LLC acquired a new stake in shares of Xenon Pharmaceuticals during the 4th quarter worth approximately $33,000. Blue Trust Inc. boosted its holdings in shares of Xenon Pharmaceuticals by 2,560.7% in the 4th quarter. Blue Trust Inc. now owns 745 shares of the biopharmaceutical company’s stock valued at $33,000 after purchasing an additional 717 shares in the last quarter. Danske Bank A S acquired a new stake in shares of Xenon Pharmaceuticals in the 3rd quarter valued at $32,000. Caitong International Asset Management Co. Ltd acquired a new stake in shares of Xenon Pharmaceuticals in the 4th quarter valued at $43,000. Finally, Aster Capital Management DIFC Ltd bought a new position in shares of Xenon Pharmaceuticals in the 3rd quarter valued at $39,000. 95.45% of the stock is currently owned by institutional investors and hedge funds.

Xenon Pharmaceuticals Trading Down 0.6%

The company has a market cap of $5.01 billion, a P/E ratio of -13.82 and a beta of 0.91. The company has a 50 day moving average price of $42.95 and a 200-day moving average price of $41.56.

Xenon Pharmaceuticals (NASDAQ:XENE) last announced its quarterly earnings data on Thursday, February 26th. The biopharmaceutical company reported ($1.31) earnings per share for the quarter, missing the consensus estimate of ($1.20) by ($0.11). During the same period last year, the company posted ($0.84) earnings per share. Equities analysts expect that Xenon Pharmaceuticals Inc. will post -3.1 earnings per share for the current year.

About Xenon Pharmaceuticals

Xenon Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company dedicated to discovering and developing novel, small‐molecule drugs targeting ion channels in the central and peripheral nervous system. The company’s research focus centers on neurological and pain disorders—including epilepsy, migraine, and neuropathic pain—by modulating key ion‐channel proteins to restore normal neuronal function. Xenon’s scientific platform draws upon advances in ion‐channel biology and structure‐based drug design to identify and optimize therapeutic candidates with the potential for improved safety and efficacy profiles compared with existing treatments.

The company’s pipeline comprises multiple preclinical and clinical programs.